Delivery of genetic therapies to affected tissues is a key challenge to developing new treatments for people with cystic fibrosis. In addition to investing in viral delivery and lipid nanoparticles, the Cystic Fibrosis Foundation is looking at the potential of a relatively new approach to delivery using an exceptionally small synthetic molecule called a polymer nanoparticle.
Site Search
Showing 1 - 3 of 3 results
News
|
|
2 min read
Funding will support a Phase 2b trial of phage therapy for chronic Pseudomonas aeruginosa lung infections.
News
|
|
2 min read
The additional funding will support a Phase 2 clinical trial for an inhaled antisense oligonucleotide drug for people with cystic fibrosis who have the splicing mutation 3849+10Kb C-to-T.
Press Release
|
|
3 min read